🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Esomeprazole Capsule

    Takeda

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  2. Fazirsiran

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  3. Febuxostat XR

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  4. Febuxostat XR

    Takeda

    Gout

    phase 1 small molecule completed

    1 trial

  5. Febuxostat XR 80 mg Capsule F1

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  6. Fucoidan (extract of Laminaria japonica)

    Takeda

    Healthy Volunteers

    phase 1 other completed

    1 trial

  7. HYQVIA

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  8. Human butyrylcholinesterase (HuBChE) derived from human plasma

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  9. INFS (Intranasal Fentanyl Spray)

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. INV21 Low Dose

    Takeda

    Hand, Foot and Mouth Disease

    phase 1 mab completed

    1 trial

  11. ITI-214 Dose A

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  12. IXAZOMIB

    Takeda

    Advanced Non-hematologic Malignancies

    phase 1 small molecule completed

    1 trial

  13. IXAZOMIB

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  14. Icatibant (30 mg)

    Takeda

    Hereditary Angioedema (HAE)

    phase 1 small molecule completed

    1 trial

  15. Ixazomib

    Takeda

    Precursor Cell Lymphoblastic Leukemia-lymphoma

    phase 1 small molecule terminated

    1 trial

  16. Ixazomib

    Takeda

    Glioblastoma

    phase 1 small molecule completed

    1 trial

  17. Ixazomib

    Takeda

    Light-Chain Amyloidosis

    phase 1 small molecule completed

    1 trial

  18. Ixazomib

    Takeda

    Lupus Nephritis

    phase 1 small molecule terminated

    1 trial

  19. Ixazomib

    Takeda

    Relapsed and Refractory Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  20. Ixazomib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  21. Ixazomib (NINLARO®) capsules / Matching placebo capsules

    Takeda

    Relapsing Remitting Multiple Sclerosis

    phase 1 small molecule active

    1 trial

  22. Ixazomib 2.5 mg

    Takeda

    Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  23. Ketamine

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  24. Ketamine

    Takeda

    Ketamine-Induced Brain Activity Changes

    phase 1 small molecule completed

    1 trial

  25. LDX + Venlafaxine XR

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  26. Lanadelumab

    Takeda

    COVID-19 Pneumonia

    phase 1 small molecule terminated

    1 trial

  27. Lanadelumab

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  28. Lansoprazole

    Takeda

    Gastroesophageal Reflux Disease

    phase 1 small molecule completed

    2 trials

  29. Lanthanum carbonate Granule Formulation

    Takeda

    End Stage Renal Disease

    phase 1 small molecule completed

    1 trial

  30. Lisdexamfetamine Dimesylate

    Takeda

    Healthy

    phase 1 small molecule terminated

    1 trial

  31. Lisdexamfetamine Dimesylate

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  32. Lisdexamfetamine Dimesylate (LDX)

    Takeda

    Attention-Deficit Hyperactivity Disorder

    phase 1 small molecule completed

    1 trial

  33. Lubiprostone

    Takeda

    Chronic Constipation, Methanogenesis

    phase 1 small molecule completed

    1 trial

  34. Lubiprostone

    Takeda

    Other Constipation

    phase 1 small molecule completed

    1 trial

  35. MEDI1341

    Takeda

    Parkinson's Disease

    phase 1 small molecule completed

    2 trials

  36. MLN0128

    Takeda

    Advanced Solid Malignancies

    phase 1 small molecule completed

    2 trials

  37. MLN0264

    Takeda

    Advanced Gastrointestinal Malignancies

    phase 1 small molecule completed

    1 trial

  38. MLN0264

    Takeda

    Advanced Gastrointestinal Carcinoma

    phase 1 small molecule terminated

    1 trial

  39. MLN1117

    Takeda

    Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  40. MLN1202

    Takeda

    Healthy Japanese and Caucasian Male Adults

    phase 1 small molecule terminated

    1 trial

  41. MLN2480

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  42. MLN2480

    Takeda

    Melanoma

    phase 1 small molecule completed

    1 trial

  43. MLN3126

    Takeda

    Safety

    phase 1 small molecule terminated

    1 trial

  44. MLN3126

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  45. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  46. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  47. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  48. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.